Osteopontin Gene Polymorphism in Stroke Patients in Egypt

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-09-30

Study Completion Date

2025-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to investigate the correlation of serum osteopontin level as a predictior and a prognostic factor in upper egyptian patients and correlation between Osteopontin Gene Polymorphisms and serum level of osteopontin in ischaemic stroke patients

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Markers of Vascular Calcification in Diabetic Nephropathy in Patients With Diabetic Nephropathy

NCT03820635

Diabetic Nephropathies Vascular Calcification

UNKNOWN

"Association Between Isokinetic Lower Extremity Muscle Strength and Bone Mineral Density in Elderly Women With and Without Osteoporosis: A Case-Control Study"

NCT07084857

Osteoporosis

COMPLETED

Effect of Manual Therapy on Low Back Pain in Osteopenic Postmenopausal Women

NCT06671665

Low Back Pain Osteopenia

RECRUITING NA

Vascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis

NCT05228262

Osteoporosis, Postmenopausal

RECRUITING NA

Exome Sequencing for Atypical Femoral Fractures

NCT02731040

Atypical Femoral Fractures Osteoporosis Bisphosphonate Therapy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Global Burden of Disease estimated that one person in four aged 25 years will have a stroke in the rest of her/his life. Among them, ischemic stroke (IS) represents 80%.

Stroke is accompanied by a neuroinflammatory response involving immune system. These long-term processes following IS are still far from being understood. So, despite the significant improvement in the diagnosis and treatment of IS, the disability and mortality rate of IS are still rising. An assessment of the prognostic risk of IS should be carried out as early as possible and corresponding interventions should be adopted clinically, in order to have a significant impact on the prognosis of patients with IS.

Predicting the outcome in individual patients solely based on clinical and radiological parameters is challenging for clinicians. Measuring blood biomarkers associated with inflammation, endothelial function, matrix remodeling, and immune functions, may improve prediction performance .

Osteopontin (OPN) is a matricellular protein participating in many physiological and pathologic processes including wound healing, bone turnover, tumor genesis, inflammation, and immune responses . It is well accepted that OPN is an important mediator in stroke pathophysiology. OPN expression is upregulated in microglia surrounding the infarcted area and in microglia and infiltrating macrophages in the infarct area. OPN and microglia seems to exhibit an intimate relationship in stroke with rather beneficial functions for the clinical outcome. However, the role of OPN in stroke-related diseases as atherosclerosis and diabetes should be further disentangled as in this early phase of disease OPN may ultimately culminate in cerebrovascular dysfunction. OPN may exert opposing effects and should be therefore addressed differently.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cases

Patients with ischaemic stroke

Gene polymorphism from blood samples

Intervention Type GENETIC

Blood samples will be collected from stroke patients within 24 hrs of stroke and normal volunteers.

Two samples will be collected serum and plasma; five ml whole blood from patients and normal volunteers and centrifuge serum samples at 1500 rpm 10 min then will be stored at - 80 °C until the day of the analysis.

Plasma samples will be stored at - 80 °C until the day of the analysis without centrifugation

Control

Healthy individuals

Gene polymorphism from blood samples

Intervention Type GENETIC

Blood samples will be collected from stroke patients within 24 hrs of stroke and normal volunteers.

Two samples will be collected serum and plasma; five ml whole blood from patients and normal volunteers and centrifuge serum samples at 1500 rpm 10 min then will be stored at - 80 °C until the day of the analysis.

Plasma samples will be stored at - 80 °C until the day of the analysis without centrifugation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gene polymorphism from blood samples

Blood samples will be collected from stroke patients within 24 hrs of stroke and normal volunteers.

Two samples will be collected serum and plasma; five ml whole blood from patients and normal volunteers and centrifuge serum samples at 1500 rpm 10 min then will be stored at - 80 °C until the day of the analysis.

Plasma samples will be stored at - 80 °C until the day of the analysis without centrifugation

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* For acute ischemic stroke cases:

( Acute ischemic stroke will be defined as an episode of focal neurological deficits lasting for more than 24 hour with relevant lesion in brain computerized tomography (CT) or magnetic resonance (MR) image\>)

1- both sex 2- Age between 18 to 70 years old. 3-symptoms suggestive of acute ischemic stroke: presenting within 24 hours of onset of these symptoms

* For old ischemic stroke:

1. both sex
2. Age between 18 to 70 years old.
3. Duration of3to 6 month of development of ischemic symptoms
* For control cases:

1. both sex
2. Healthy people
3. Age: above 18 years old

Exclusion Criteria

Patients with a previous history of stroke; Patients with hemorrhagic stroke. Patients with coronary heart disease, heart failure, chronic inflammation, intracranial infection/brain tumor and malignant tumor.

Patients with liver, kidney and other important organ dysfunction. Patients with severe abnormal coagulation function

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No